That would be my guess, since actual evidence shows that vaccinated people are infectious for a significantly shorter period of time:
https://www.cdc.gov/coronavirus/2019-ncov/variants/delta-var...
You are trying to condense a very complex scenario into a very simple argument.
"With the BNT162b2 vaccine, the effectiveness of two doses was 93.7% (95% CI, 91.6 to 95.3) among persons with the alpha variant and 88.0% (95% CI, 85.3 to 90.1) among those with the delta variant. With the ChAdOx1 nCoV-19 vaccine, the effectiveness of two doses was 74.5% (95% CI, 68.4 to 79.4) among persons with the alpha variant and 67.0% (95% CI, 61.3 to 71.8) among those with the delta variant." https://www.nejm.org/doi/full/10.1056/NEJMoa2108891
On the contrary, I'm actually tightening my estimation to "more than 67%" (95% CI @ 61.3%-71.8%). BNT162b2 is Pfizer, ChAdOx1 is AstraZeneca.
> (...) also are less likely to develop symptoms and so will most likely not isolate when you are infected.
Yup, so multiply those likelihoods and let me know what number you arrived at and what assumptions did you take so that we can compare some concrete estimations. Or share some article that tried to estimate this.
> You are trying to condense a very complex scenario into a very simple argument.
I'm willing to be convinced otherwise by some data, so far the only thing you're offering is an opinion.